O'Grady Michael 4

What Happened

• Michael O'Grady, a director of Abbott Laboratories (ABT), received equity awards on April 24, 2026: 2,286 restricted stock units (RSUs) and a derivative award for 5,929 shares (stock option). Both awards show an acquisition price of $0.00 (no cash paid). The filing was submitted to the SEC on April 28, 2026.
• These are grants (awards), not open-market purchases or sales — they are compensation/benefit transactions rather than trading signals.

Key Details

• Transaction date: 2026-04-24; Form 4 filed: 2026-04-28.
• Awards reported: 2,286 RSUs (grant, $0.00) and 5,929 derivative shares (option grant, $0.00).
• Shares owned after transaction: Not specified in the details provided in this summary (check the full Form 4 for beneficial ownership totals).
• Footnotes: F1 — RSU award under the 2026 Incentive Stock Program; RSUs will be paid one-for-one in Abbott common shares upon the earlier of separation from service, death, or a change in control. F2 — Stock option grant under the Program; the award was made in a transaction exempt from Section 16 under Rule 16b-3.
• Filing timeliness: The Form 4 was filed four days after the transaction date. Section 16 generally requires reporting within two business days; this filing may therefore be outside that usual window (review the official filing for any tardiness notation).

Context

• RSUs: These do not immediately convert to tradable shares; they pay out in common stock only when the specified vesting/trigger events occur (here: separation, death, or change in control). They are compensation, not a cash purchase.
• Options/derivatives: The 5,929-share entry represents an option/derivative grant, not an immediate exercise or sale. No shares were sold or exercised in this filing.
• For retail investors: Awards to directors are common as part of board compensation. They are informational but do not necessarily indicate a director buying or selling stock for investment reasons.